How to buy Intec Pharma stock (NTEC)

Intec Pharma is a biotechnology business based in the US. Intec Pharma shares (NTEC) are listed on the NASDAQ and all prices are listed in US Dollars. Intec Pharma employs 36 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Intec Pharma stock

Buy Intec Pharma stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Intec Pharma stock price (NASDAQ: NTEC)

Use our graph to track the performance of NTEC stocks over time.

Intec Pharma shares at a glance

• Key figures

Information last updated 2021-09-26.

52-week range	$0.00 - $0.00
50-day moving average more info button	$12.85
200-day moving average more info button	$16.50
Wall St. target price	$13.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-14.56

Is it a good time to buy Intec Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Intec Pharma financials

Gross profit TTM	$0
Return on assets TTM	-45.7%
Return on equity TTM	-113.34%
Profit margin	0%
Book value	$10.08
Market Capitalization more info button	$17.7 million

TTM: trailing 12 months

Intec Pharma share dividends

We're not expecting Intec Pharma to pay a dividend over the next 12 months.

Have Intec Pharma's shares ever split?

Intec Pharma's shares were split on a 1:4 basis on 26 July 2021 . So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Intec Pharma shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Intec Pharma shares which in turn could have impacted Intec Pharma's share price.

Intec Pharma share price volatility

Over the last 12 months, Intec Pharma's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intec Pharma's is 1.1398. This would suggest that Intec Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Intec Pharma overview

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which has completed a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck Sharp & Dohme for the development of Accordion Pill; and a cannabinoid research collaboration agreement with GW Research Limited to explore an undisclosed research program using the Accordion Pill platform. The company was formerly known as Intec Pharmaceuticals (2000) Ltd.

Frequently asked questions

null
What percentage of Intec Pharma is owned by insiders or institutions?
Currently 1.793% of Intec Pharma shares are held by insiders and 14.654% by institutions. How many people work for Intec Pharma?
Latest data suggests 36 work at Intec Pharma. When does the fiscal year end for Intec Pharma?
Intec Pharma's fiscal year ends in December. Where is Intec Pharma based?
Intec Pharma's address is: RMPE building, Jerusalem, Israel, 9777512 What is Intec Pharma's ISIN number?
Intec Pharma's international securities identification number is: US45828B1008 What is Intec Pharma's CUSIP number?
Intec Pharma's Committee on Uniform Securities Identification Procedures number is: M53644106